Acute Ischemic Stroke Pipeline Therapeutics Assessment Review H2 2015

1. Acute Ischemic Stroke - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 29-Jul-2015 No. of pages: 110 Single User License: US $2000 Browse more Reports on Central Nervous System Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Acute Ischemic Stroke - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Acute Ischemic Stroke - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research : AB Science SA, AstraZeneca Plc, Biogen, Inc., D-Pharm Ltd., Daiichi Sankyo Company, Limited, DiaMedica Inc., Digna Biotech, S.L., Glucox Biotech AB, Grifols, S.A., Lumosa Therapeutics Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pharmicell Co., Ltd., PhytoHealth Corporation, Remedy Pharmaceuticals, Inc., Simcere Pharmaceutical Group, Stemedica Cell Technologies, Inc. and ZZ Biotech, LLC Drugs Profile Discussed in this Research : 3K3A-APC, Cerecellgram-Stroke, DB-017, DM-199, DS-1040, glyburide, HBN-1, Human Plasmin, LT-3001, masitinib, Mesenchymal Stem Cells, MP-124, natalizumab, Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke, PHN-014, Recombinant Plasmin, SIM-071201, Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke, Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke, THR-18, ticagrelor and TS-01 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Acute Ischemic Stroke - Pipeline Review, H2 2015 Scope For Acute Ischemic Stroke - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Acute Ischemic Stroke and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Acute Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Acute Ischemic Stroke - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Acute Ischemic Stroke - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441